Shares of Roche Holding AG (OTCMKTS:RHHBY) have been assigned a consensus rating of “Hold” from the thirteen brokerages that are covering the stock, Marketbeat reports. Four equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $38.00.
A number of research firms recently weighed in on RHHBY. Sanford C. Bernstein cut shares of Roche from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 10th. Zacks Investment Research cut shares of Roche from a “hold” rating to a “sell” rating in a research note on Wednesday, April 11th. Morgan Stanley cut shares of Roche from an “equal weight” rating to an “underweight” rating in a research note on Tuesday, March 27th. Finally, ValuEngine cut shares of Roche from a “buy” rating to a “hold” rating in a research note on Monday, February 5th.
Get Roche alerts:
Shares of Roche stock traded down $0.02 on Monday, hitting $27.93. 4,455,142 shares of the company’s stock were exchanged, compared to its average volume of 1,563,407. The stock has a market capitalization of $190.49 billion, a PE ratio of 14.32, a P/E/G ratio of 1.85 and a beta of 0.55. Roche has a 1 year low of $27.48 and a 1 year high of $34.67. The company has a debt-to-equity ratio of 0.55, a current ratio of 1.42 and a quick ratio of 1.09.
A number of hedge funds have recently made changes to their positions in the business. PVG Asset Management Corp purchased a new stake in Roche in the 1st quarter worth $2,218,000. Hikari Power Ltd lifted its stake in Roche by 6.4% in the 1st quarter. Hikari Power Ltd now owns 166,700 shares of the company’s stock worth $4,772,000 after purchasing an additional 10,100 shares in the last quarter. Osher Van de Voorde Investment Management lifted its stake in Roche by 3.1% in the 1st quarter. Osher Van de Voorde Investment Management now owns 249,414 shares of the company’s stock worth $7,139,000 after purchasing an additional 7,475 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Roche by 3.7% in the 1st quarter. Fisher Asset Management LLC now owns 16,780,072 shares of the company’s stock worth $479,912,000 after purchasing an additional 591,921 shares in the last quarter. Finally, Todd Asset Management LLC lifted its stake in Roche by 9.4% in the 1st quarter. Todd Asset Management LLC now owns 116,200 shares of the company’s stock worth $3,326,000 after purchasing an additional 10,000 shares in the last quarter. Institutional investors and hedge funds own 0.60% of the company’s stock.
Roche Holding AG diagnostics and pharmaceuticals businesses in Switzerland, Germany, and rest of Europe. It offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, liver, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus diseases.